{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:37:58Z","timestamp":1793284678209,"version":"4.5.0"},"reference-count":28,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"DOI":"10.3201\/eid1806.120116","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T14:45:01Z","timestamp":1337265901000},"page":"901-907","source":"Crossref","is-referenced-by-count":328,"title":["Iatrogenic Creutzfeldt-Jakob Disease, Final Assessment"],"prefix":"10.3201","volume":"18","author":[{"given":"Paul","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Brandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosikazu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Will","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ladogana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pocchiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen W.","family":"Leschek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Schonberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","published-online":{"date-parts":[[2012,6]]},"reference":[{"key":"key-10.3201\/eid1806.120116-201205170400-R1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJM197403212901220","article-title":"Letter: possible person-to-person transmission of Creutzfeldt-Jakob disease.","volume":"290","author":"Duffy","year":"1974","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid1806.120116-201205170400-R2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1212\/01.wnl.0000231528.65069.3f","article-title":"Iatrogenic Creutzfeldt-Jakob disease: the waning of an era.","volume":"67","author":"Brown","year":"2006","journal-title":"Neurology"},{"key":"key-10.3201\/eid1806.120116-201205170400-R3","first-page":"85","article-title":"Human growth hormone therapy and Creutzfeldt-Jakob disease: a drama in three acts.","volume":"81","author":"Brown","year":"1988","journal-title":"Pediatrics"},{"key":"key-10.3201\/eid1806.120116-201205170400-R4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1357","article-title":"Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977.","author":"Abrams","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"key-10.3201\/eid1806.120116-201205170400-R5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1440-1789.2006.00638.x","article-title":"Increased asymmetric pulvinar magnetic resonance imaging signals in Creutzfeldt-Jakob disease with florid plaques following a cadaveric dura mater graft.","volume":"26","author":"Wakisaka","year":"2006","journal-title":"Neuropathology"},{"key":"key-10.3201\/eid1806.120116-201205170400-R6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/humu.9157","article-title":"Prion susceptibility and protective alleles exhibit marked geographic differences.","volume":"22","author":"Soldevila","year":"2003","journal-title":"Hum Mutat"},{"key":"key-10.3201\/eid1806.120116-201205170400-R7","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1034\/j.1600-0404.2003.00199.x","article-title":"The normal population distribution of PRNP codon 129 polymorphism.","volume":"108","author":"Nurmi","year":"2003","journal-title":"Acta Neurol Scand"},{"key":"key-10.3201\/eid1806.120116-201205170400-R8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3378\/1534-6617(2008)80[181:PDOTMA]2.0.CO;2","article-title":"Population distribution of the methionine allele at the PRNP codon 129 polymorphism in Europe and the Middle East.","volume":"80","author":"Mercier","year":"2008","journal-title":"Hum Biol"},{"key":"key-10.3201\/eid1806.120116-201205170400-R9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/353801b0","article-title":"CJD discrepancy.","volume":"353","author":"Doh-ura","year":"1991","journal-title":"Nature"},{"key":"key-10.3201\/eid1806.120116-201205170400-R10","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S0140-6736(03)13867-6","article-title":"Distribution of codon 129 genotype in human growth hormone\u2013treated CJD patients in France and the UK.","volume":"362","author":"Brandel","year":"2003","journal-title":"Lancet"},{"key":"key-10.3201\/eid1806.120116-201205170400-R11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1136\/jnnp.2007.122267","article-title":"Iatrogenic Creutzfeldt-Jakob disease 22 years after human growth hormone therapy: clinical and radiological features.","volume":"79","author":"Furtner","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.3201\/eid1806.120116-201205170400-R12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1212\/01.wnl.0000266624.63387.4a","article-title":"Clinical features and diagnosis of dura mater graft\u2013associated Creutzfeldt-Jakob disease.","volume":"69","author":"Noguchi-Shinohara","year":"2007","journal-title":"Neurology"},{"key":"key-10.3201\/eid1806.120116-201205170400-R13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/j.1440-1789.2008.00987.x","article-title":"Dura mater graft\u2013associated Creutzfeldt-Jakob disease in Japan: clinicopathological and molecular characterization of the two distinct subtypes.","volume":"29","author":"Yamada","year":"2009","journal-title":"Neuropathology"},{"key":"key-10.3201\/eid1806.120116-201205170400-R14","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1093\/brain\/awq216","article-title":"Prospective 10-year surveillance of human prion diseases in Japan.","volume":"133","author":"Nozaki","year":"2010","journal-title":"Brain"},{"key":"key-10.3201\/eid1806.120116-201205170400-R15","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1212\/01.WNL.0000160117.56690.B2","article-title":"Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, Australia, and Canada.","volume":"64","author":"Ladogana","year":"2005","journal-title":"Neurology"},{"key":"key-10.3201\/eid1806.120116-201205170400-R16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1476-069X-7-31","article-title":"Risk behaviors in a rural community with a known point-source exposure to chronic wasting disease.","volume":"7","author":"Garruto","year":"2008","journal-title":"Environ Health"},{"key":"key-10.3201\/eid1806.120116-201205170400-R17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0140-6736(89)90035-4","article-title":"Infectivity of unconventional viruses in dura mater.","volume":"1","author":"Diringer","year":"1989","journal-title":"Lancet"},{"key":"key-10.3201\/eid1806.120116-201205170400-R18","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000181894","article-title":"Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination.","volume":"35","author":"Pocchiari","year":"1991","journal-title":"Horm Res"},{"key":"key-10.3201\/eid1806.120116-201205170400-R19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.biologicals.2007.04.005","article-title":"Prion removal by nanofiltraion under different experimental conditions.","volume":"36","author":"Yunoki","year":"2008","journal-title":"Biologicals"},{"key":"key-10.3201\/eid1806.120116-201205170400-R20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03425.x","article-title":"Comparison of nanofiltration efficacy in reducing infectivity of centrifuged versus ultracentrifuged 263K scrapie-infected brain homogenates in \u201cspiked\u201d albumin solutions.","author":"Cardone","year":"2011","journal-title":"Transfusion"},{"key":"key-10.3201\/eid1806.120116-201205170400-R21","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/S0140-6736(06)69897-8","article-title":"Reduction in infectivity of endogenous transmissible spongiform encephalopathies present in blood by adsorption to selective affinity resins.","volume":"368","author":"Gregori","year":"2006","journal-title":"Lancet"},{"key":"key-10.3201\/eid1806.120116-201205170400-R22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2011.01563.x","article-title":"Removal of prion infectivity by affinity ligand chromatography during OctaplasLG manufacturing\u2014results from animal bioassay studies.","author":"Heger","year":"2011","journal-title":"Vox Sang"},{"key":"key-10.3201\/eid1806.120116-201205170400-R23","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3201\/eid1712.110607","article-title":"Candidate cell substrates, vaccine production, and transmissible spongiform encephalopathies.","volume":"17","author":"Piccardo","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"key-10.3201\/eid1806.120116-201205170400-R24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(04)16810-4","article-title":"Novel methods for disinfection of prion-contaminated medical devices.","volume":"364","author":"Fichet","year":"2004","journal-title":"Lancet"},{"key":"key-10.3201\/eid1806.120116-201205170400-R25","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jhin.2007.08.020","article-title":"Prion inactivation using a new gaseous hydrogen peroxide sterilization process.","volume":"67","author":"Fichet","year":"2007","journal-title":"J Hosp Infect"},{"key":"key-10.3201\/eid1806.120116-201205170400-R26","first-page":"418","article-title":"Reduction of risk of prion transmission on surgical devices with effective cleaning processes.","volume":"15","author":"Fichet","year":"2007","journal-title":"Zentr Steril."},{"key":"key-10.3201\/eid1806.120116-201205170400-R27","doi-asserted-by":"crossref","unstructured":"Orr\u00fa CD, Wilham JM, Raymond LD, Kuhn F, Schroeder B, Raeber AJ, Prion disease blood test using immunoprecipitation and improved quaking-induced conversion. MBiol. 2011;3:e00078-11 [cited 2012 Mar 31]. http:\/\/mbio.asm.org\/content\/2\/3\/e00078-11.full","DOI":"10.1128\/mBio.00078-11"},{"key":"key-10.3201\/eid1806.120116-201205170400-R28","doi-asserted-by":"crossref","unstructured":"Orr\u00fa CD, Wilham JM, Vascellari S, Hughson AG, Caughey B. New generation QuIC assays for prion seeding activity. Prion. 2012;6. Epub ahead of print.","DOI":"10.4161\/pri.19430"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/18\/6\/12-0116_intro","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T23:14:51Z","timestamp":1733267691000},"score":1,"resource":{"primary":{"URL":"http:\/\/wwwnc.cdc.gov\/eid\/article\/18\/6\/12-0116_intro.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6]]}},"URL":"https:\/\/doi.org\/10.3201\/eid1806.120116","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}